

3

**COPY OF PAPERS
ORIGINALLY FILED**



DOCKET 50174-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Adam LERNER EXAMINER:

SERIAL NO.: 10/060,759 GROUP: 1614

FILED: January 30, 2002

FOR: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, applicants are submitting simultaneously herewith a Sequence Listing. Please amend the application as follows.

In the Specification:

Please replace the 2nd full paragraph on page 12, beginning at line 19 and ending at page 13, line 12 with the following:

RNA was isolated from CLL or whole mononuclear cells using Ultraspec reagent (Biotecx, Houston, TX). cDNA was synthesized from 10 ug of total RNA using oligo d(T) primers and Maloney murine leukemia virus reverse transcriptase in a final volume of 40 uL (Stratagene, La Jolla, CA). One mL of the first strand cDNA product was then used as template for PCR amplification with AmpliTaq DNA polymerase (Roche Molecular Systems,